The Plasma Chromogranin A Level Predicts Survival and Tumor Response in Patients with Gastroenteropancreatic Neuroendocrine Tumors

#804

Introduction: The plasma chromogranin A (CgA) level is a reliable biomarker for identifying patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Aim(s): To measure the baseline value and changes during antitumor therapy of the CgA level in patients with advanced GEP-NETs.

Materials and methods: Sixty patients with advanced GEP-NET treated at a single medical center between April 2010 and April 2013 were retrospectively enrolled. The plasma CgA level was measured and imaging performed concurrently at baseline and at regular intervals after antitumor therapy. The plasma CgA level was analyzed for correlation with the patient’s clinical outcome and the tumor response.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Chou W

Authors: Chou W, Chen J, Hsu J, Chen T, Hung Y,

Keywords: neuroendocrine tumor, biomarker, chromogranin A,